Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inventiva ( (IVA) ) just unveiled an announcement.
On October 20, 2025, Inventiva S.A. announced the upcoming Ordinary and Extraordinary General Meeting scheduled for November 27, 2025, in Paris, France. The meeting will address several key agenda items, including the approval of the CEO’s compensation policy, a settlement agreement with Mr. Frédéric Cren, and the authorization for the Board to grant share options. These resolutions reflect Inventiva’s strategic focus on aligning executive compensation with company performance and expanding its capital structure to support future growth, potentially impacting shareholder value and employee incentives.
The most recent analyst rating on (IVA) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score is primarily impacted by its poor financial performance, which poses significant risks to its sustainability. While there are positive developments in clinical trials and strategic partnerships, these are overshadowed by financial instability and bearish technical indicators.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva S.A. operates in the pharmaceutical industry, focusing on the development of oral small molecule therapies for the treatment of fibrotic, metabolic, and autoimmune diseases. The company is known for its innovative approach in targeting nuclear receptors, transcription factors, and epigenetic modulation, with a market focus on addressing unmet medical needs.
Average Trading Volume: 74,115
Technical Sentiment Signal: Buy
Current Market Cap: $556.7M
See more insights into IVA stock on TipRanks’ Stock Analysis page.